Trending Now - Innovative Drug Shows Potential in Pancreatic Cancer Treatment
WHO:
Nature - Ecaterina Dumbrava, an oncologist at the University of Texas MD Anderson Cancer Center in Houston, described the presentation of the trial results as "really emotional."
ABC News - Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research and Gastrointestinal Cancer Center at Dana-Farber Cancer Institute.
ABC News - Jim, a patient who participated in the clinical trial.
ABC News - Carla Walker, another patient enrolled in the trial.
WHAT:
Nature - The experimental drug daraxonrasib disarms all three members of the RAS family of proteins, which are linked to some of the deadliest cancers.
Nature - The trial results were met with a long standing ovation at the American Society of Clinical Oncology annual meeting.
ABC News - An experimental drug, daraxonrasib, nearly doubled overall survival in a Phase 3 clinical trial for metastatic pancreatic cancer.
ABC News - Patients treated with daraxonrasib had a median overall survival of 13.2 months compared to 6.7 months for those receiving chemotherapy.
ABC News - The treatment reduced the risk of death by 60%.
NBC News - The treatment could potentially be used against other types of cancer, including colon, ovarian, and lung cancers.
ABC News - The global Phase 3 trial enrolled 500 patients with metastatic pancreatic cancer who had previously received one line of chemotherapy.
WHERE:
ABC News - Findings presented at the American Society of Clinical Oncology annual meeting.
ABC News - Published simultaneously in the New England Journal of Medicine.
WHEN:
ABC News - The findings were presented on a Sunday at the American Society of Clinical Oncology annual meeting.
ABC News - The FDA granted permission for an expanded access program earlier in the month.
WHY:
ABC News - The trial aims to help patients live longer and better with fewer side effects and symptoms from cancer.
HOW:
Nature - Daraxonrasib was developed by Revolution Medicines in Redwood City, California.
ABC News - Daraxonrasib is an oral targeted therapy designed to block RAS proteins, which are key in driving pancreatic cancer growth.
(UPDATED June 2, 2026 12:19 UTC)
At the American Society of Clinical Oncology annual meeting, the trial results for the experimental drug daraxonrasib were met with a long standing ovation, highlighting the significance of this breakthrough. Oncologist Ecaterina Dumbrava from the University of Texas MD Anderson Cancer Center described the presentation of these results as "really emotional," as daraxonrasib disarms all three members of the RAS family of proteins linked to some of the deadliest cancers. This promising drug was developed by Revolution Medicines in Redwood City, California.
--
(UPDATED June 2, 2026 01:43 UTC)
A groundbreaking Phase 3 clinical trial has shown that an experimental drug called daraxonrasib nearly doubled overall survival for patients with metastatic pancreatic cancer, achieving a median survival of 13.2 months compared to just 6.7 months for those receiving standard chemotherapy. The treatment, which significantly reduced the risk of death by 60%, was presented at the American Society of Clinical Oncology annual meeting and could potentially be effective against other cancers like colon, ovarian, and lung cancers. Dr. Brian Wolpin, the director of the Hale Family Center for Pancreatic Cancer Research, along with patients Jim and Carla Walker, participated in this trial that aimed to improve the quality of life for cancer patients with fewer side effects.